Cyanotech Reports Positive Clinical Results from Use of BioAstin for Rheumatoid Arthritis; BioAstin Shown to Significantly Reduce Joint Pain

KAILUA-KONA, Hawaii--(BW HealthWire)--May 22, 2002--Cyanotech Corporation (Nasdaq NMS:CYAN) reported today that in a clinical trial BioAstin(R) has been shown to significantly reduce joint pain and improve physical performance in people with rheumatoid arthritis.

The double-blind, placebo-controlled clinical study was conducted by the Health Research and Studies Center of Los Altos, California. The results of the study are expected to be presented at the College of Nutrition scientific meeting in October 2002.

Rheumatoid arthritis is a chronic destructive disorder that is the most common form of inflammatory arthritis. The disease has a substantial effect in terms of disability and productivity loss as well as cost. According to the Arthritis Foundation, over two million Americans suffer from rheumatoid arthritis while musculoskeletal conditions such as rheumatoid arthritis cost the U.S. economy $65 billion per year in medical care and indirect expenses, such as lost wages and production.

The active ingredient in BioAstin, natural astaxanthin, has been shown to be a potent antioxidant over 500 times stronger than vitamin E and 10 times stronger than beta-carotene. Joint pain and joint inflammation can be caused by oxidative damage as a result of free radicals. Free radicals are generated from exposure to toxic pollutants or by the body itself as part of an immune response. The potent antioxidant properties of BioAstin may help neutralize these free radicals and minimize oxidative damage to joints.

"This study, combined with the results of other studies showing positive effects from using BioAstin on carpal tunnel syndrome and knee soreness, adds to the growing body of scientific evidence that BioAstin offers a viable natural alternative for persons who suffer from a variety of joint pains," said Gerald R. Cysewski, PhD., chairman, president and CEO of Cyanotech. "These results should provide Twinlab Corporation and other major dietary supplement companies that are beginning to include, or plan to include, BioAstin in their products with further scientific support to develop products for the $6.8 billion joint health market," Dr. Cysewski noted.

Recently, a clinical study showed patients using BioAstin reporting a reduction in both the severity and duration of pain from Carpal Tunnel Syndrome. Earlier, a clinical trial linked BioAstin with preventing knee soreness after strenuous leg exercises and with a significantly stronger immune system response.

Cyanotech's current production capacity for BioAstin ranges from $12 million to $40 million annually, depending on the product mix, at current selling prices.

-- Cyanotech Corporation, the world's leader in microalgae technology, produces high-value natural products from microalgae, and is the world's largest commercial producer of natural astaxanthin (pronounced "asta-zan-thin") from microalgae. Products include BioAstin(R) natural astaxanthin, a powerful antioxidant with expanding applications as a human nutraceutical; NatuRose(R) natural astaxanthin for the aquaculture and animal feed industries; Spirulina Pacifica(R), a nutrient-rich dietary supplement; and phycobiliproteins, which are fluorescent pigments used in the immunological diagnostics market. Spirulina and BioAstin are sold directly online through and as well as through resellers worldwide in over 30 countries. Corporate and product information is available at

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.